BGIM
BLUE

Boussard & Gavaudan Investment Management’s bluebird bio BLUE Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-895
Closed -$1.05M – 24
2019
Q3 		$1.05M Buy
+895
New +$1.37M 0.14% 25

Other funds holding BLUE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boussard & Gavaudan Investment Management's BLUE Position: Q4 2019 in Review

Boussard & Gavaudan Investment Management sold out of bluebird bio (BLUE) in Q4 2019, closing a stake of 895 shares — an estimated $1.05M sold.

Boussard & Gavaudan Investment Management first reported a position in BLUE in Q3 2019 and held it in 1 quarter. The position peaked at $1.05M in Q3 2019. 274 funds tracked by Wall St. Rank hold BLUE as of Q4 2019.

  • Boussard & Gavaudan Investment Management reported no remaining bluebird bio position as of Q4 2019 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 895 bluebird bio shares in Q4 2019, an estimated $1.05M.
  • Boussard & Gavaudan Investment Management first reported a position in bluebird bio in Q3 2019 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's bluebird bio position peaked at $1.05M in Q3 2019.
  • 274 funds tracked by Wall St. Rank held bluebird bio as of Q4 2019.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.